-->

Tag: graft-versus-host disease prevention

Home / graft-versus-host disease prevention

Categories

Omidubicel is approved by USFDA to reduce time to neutrophil recovery and infection in patients with hematologic malignancies

May 2023: Omidubicel-onlv (Omisirge, Gamida Cell Ltd.) was approved by the Food and Drug Administration for use in adult and paediatric patients (12 years of age and older) with hematologic malignanc...
graft-versus-host-disease-prevention

hematopoietic stem cell transplantation (allogeneic)


graft-versus-host-disease-prevention

Scan the code